The effect of Atomoxetine on Cognitive Function of Inpatient and Outpatient Multiple Sclerosis

1.Determining the frequency of cognitive disorders in the study population in the group of Atomoxetine and Placebo 2.Comparison of changes in cognitive impairment before and after drug administration between Placebo and Atomoxetine

Clinical trial with control group,double blind, randomized, phase 3 ,with a parallel group design of 52 patients. For randomization, a randomized block method with 4 blocks was used

.Patients referred to outpatient or inpatient clinics of Golestan Hospital in Ahvaz are selected after reviewing the inclusion and exclusion criteria. Initially, McFims test patients are taken in a double-blind study. The number of each patient is placed on the drug package based on the software randomization list. Also, two placebo and Atomoxetine drugs are packaged in such a way that the patient does not know the name of the drug and is given to patients by a nurse not related to the research. In such a way that the attending physician is not aware of the medication provided to each patient.Group A, which consists of 26 patients selected by an uninformed person, will be treated with Atomoxetine for three months, and group B, which includes 26 patients, will be treated by an uninformed person. Will be selected and treated with placebo. At the beginning and end of 3 months, McFims test is performed for patients.

Entry requirements; Age between 18 and 55 years; Testable measurable cognitive impairment McFims attributed to multiple sclerosis; Diagnosis of multiple sclerosis based on McDonald's criteria No entry conditions; Continuous use of stimulants; Contraindications to the use of Atomoxetine

Group A will be treated with Atomoxetine and group B will be treated with Placebo

Language; executive function; processing speed ; functional memory; new learning power

This study is a randomized controlled clinical trial. In this study, patients will be assigned to each of the treatment groups by a randomized block method using 4 blocks Which are selected from patients referring to the clinic or outpatient or inpatient clinics of Golestan Hospital in Ahvaz after reviewing the inclusion and exclusion criteria Exits are selected. At the beginning of the study, patients are tested with McFimes. Randomization or random assignment of patients to each treatment group will be done by randomized block method using 4 blocks by winpepi 11.4 software. Subjects were randomly divided into two groups based on the method of quadruple random blocks. The study is a double-blind study in the sense that the patient and the medical staff are unaware of the type of treatment assigned to each person. The number of each patient is placed on the drug package based on the software randomization list. Also, two placebo and Atomoxetine drugs are packaged in such a way that the patient does not know the name of the drug and is given to patients by a nurse not related to the research. In such a way that the attending physician is not aware of the medication provided to each patient. The Beck test is used to check for depression, and people who score 9 on this test are excluded from the study. Patients who will not be able to continue their study due to intolerance to Atomoxetine will be excluded from the study.

The study is a double-blind study in the sense that the patient and the medical staff are unaware of the type of treatment assigned to each person. In this study, patients will be assigned to each treatment group using a randomized block method using 4 blocks. The number of each patient is placed on the drug package based on the software randomization list. Also, two placebo and Atomoxetine drugs are packaged in such a way that the patient does not know the name of the drug and is given to patients by a nurse not related to the research. In such a way that the attending physician is not aware of the medication provided to each patient.

All data is potentially shareable after unidentified individuals

Access period starts 3 months after the results are published

It will be available to researchers working in academic and scientific institutions

The use of documentation is permitted for non academic neurologists and other specialist physicians

Effat Amouzadeh, contact number 09106530322, email effatamouzadeh@gmail.com, address of residence unit 11, Mohammad 5 Residential complex, Between Eghbal st and Nosrat st, Isfahan Ave, Golestan District, Postal Code 6136913847

Sending an email or letter to Effat Amouzadeh's mailing address, will be responsive within a week